Last reviewed · How we verify

Ortho-McNeil Janssen Scientific Affairs, LLC — Portfolio Competitive Intelligence Brief

Ortho-McNeil Janssen Scientific Affairs, LLC pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
OROS MPH Tablets OROS MPH Tablets marketed Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor Dopamine transporter (DAT); norepinephrine transporter (NET) Psychiatry / Neurology
OROS MPH OROS MPH marketed Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor Dopamine transporter (DAT); norepinephrine transporter (NET) Psychiatry / Neurology
tapentadol IR tapentadol IR phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Ortho-McNeil Janssen Scientific Affairs, LLC:

Cite this brief

Drug Landscape (2026). Ortho-McNeil Janssen Scientific Affairs, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ortho-mcneil-janssen-scientific-affairs-llc. Accessed 2026-05-17.

Related